Resmed's Record Year: A Masterclass in Growth, Strategy, and Risk

SAN DIEGO, CA – August 06, 2026 – Resmed Inc. has once again demonstrated its formidable position in the medical technology landscape, closing its 2026 fiscal year with a set of figures that would be the envy of any competitor. A record $1.5 billion in fourth-quarter revenue and a 17% surge in full-year non-GAAP earnings per share paint a picture of a company firing on all cylinders. Yet, to see these results as just another strong earnings report is to miss the intricate strategy unfolding beneath the surface. Beyond the impressive top and bottom lines, Resmed is executing a calculated evolution—shedding non-core assets, acquiring new capabilities, and navigating the inevitable operational turbulence that comes with market leadership, all while doubling down on shareholder returns.

A Financial Powerhouse Outpacing the Market

Resmed’s financial performance is not just strong; it’s dominant. The company's 10% full-year revenue growth to $5.7 billion doesn't just look good in isolation—it significantly outstrips the broader medtech industry's average growth, which hovers around 6-7%. When compared to a diversified giant like Philips, which has projected mid-single-digit growth, Resmed's performance appears even more robust. This growth is a testament to what CEO Mick Farrell described as “continued momentum of our global business, sustained demand for our market-leading products, and disciplined execution of our strategy.”

The demand is undeniable. Global device revenue grew 9% for the year, while masks and other accessories surged by an impressive 13%. This isn't a company riding a single product wave; it's seeing broad-based strength across its portfolio and geographies. The Americas region grew 9%, while the Rest of World segment expanded 13% (7% in constant currency), indicating a well-balanced global footprint.

This operational success is being directly translated into shareholder value. The company returned a staggering $1.0 billion to shareholders in fiscal 2026 through buybacks and dividends—a 70% increase from the prior year. More telling is the forward guidance: Resmed plans to return over $1.85 billion in fiscal 2027, backed by a fresh 10% hike in its quarterly dividend to $0.66 per share. This isn't just a reward for a good year; it's a loud and clear statement of management's confidence in sustained, robust cash generation.

Strategic Pruning and Planting for Future Growth

Perhaps the most telling aspect of Resmed's recent activity lies in its portfolio management. The announcement of an agreement to sell its MatrixCare business, which provides software for residential care, is a pivotal move. While the Residential Care Software segment grew, its 5% annual growth pales in comparison to the double-digit expansion in the core Sleep and Breathing Health business. The divestiture is a classic strategic play: prune slower-growing branches to channel resources toward the core trunk and its most promising new shoots. This move sharpens Resmed's focus squarely on the high-growth, high-innovation arena of home-based sleep and respiratory care, where it commands a leading position.

Simultaneously, the company is planting new seeds. The completed acquisition of Noctrix Health, a medical device firm with a wearable therapeutic for Restless Leg Syndrome (RLS), is a brilliant strategic adjacency. It expands Resmed's total addressable market beyond its traditional stronghold of sleep apnea, moving into a related sleep disorder that leverages its existing sales channels and brand equity. This isn't a random diversification; it's a calculated expansion of its sleep-health ecosystem, reinforcing its vision to be the comprehensive solution provider for a good night's sleep. The partnership with ŌURA, known for its smart ring, further cements this ecosystem strategy, focusing on education and creating new pathways to care.

Navigating the Headwinds of Operational Reality

No company of Resmed's scale operates without challenges, and the fourth-quarter report provides a transparent look at the costs of leadership in a highly regulated industry. A notable line item was the $41.885 million charge for 'Astral field safety notification expenses'. This expense, related to its Astral life support ventilators, was the primary reason for the dip in GAAP gross margin to 58.8%. While a significant sum, it's a necessary cost of ensuring patient safety and regulatory compliance. The more important metric for investors tracking core performance, the non-GAAP gross margin, actually expanded by 90 basis points, showcasing underlying productivity gains.

This balancing act between managing legacy issues and driving future growth is a hallmark of a mature market leader. It also helps explain the market's seemingly paradoxical reaction to the stellar report. Despite beating analyst estimates, Resmed's stock dipped in after-hours trading. This reaction likely has less to do with the reported numbers and more to do with the unwritten story of future expectations. Investors, having priced in excellence, are now scrutinizing the sustainability of mask growth rates and the outlook for device sales in key markets. The operational charge, while managed, serves as a reminder of the inherent risks in the medical device sector.

Ultimately, Resmed's fiscal 2026 story is one of aggressive, intelligent execution. The company is leveraging its financial strength not just to reward investors today, but to reshape its own future through strategic acquisitions and divestitures. It is navigating the complexities of a global supply chain and regulatory environment while continuing to launch innovative products like the AirSense 11 and AirCurve 11 series in new markets. As Farrell stated, the goal is to “leverage our global scale and enhance our digital capabilities to benefit our patients, providers, and customers.” The record-breaking numbers are the result; the strategy is the cause, and it provides a compelling blueprint for success in the 21st-century healthcare economy.